Comprehensive Study Notes: Comfort and Pain Management
Epidemiology and the Systemic Impact of Pain
Prevalence of Chronic Pain in the United States:
Current epidemiological reports indicate that of adults in the United States experience chronic pain.
High-impact chronic pain—defined as persistent pain that frequently limits work, social, self-care, and recreational activities—affects approximately of adults in the United States (Dahlhamer et al., 2018; Zelaya et al., 2020).
Geographic distribution and urbanization significantly influence pain reporting: adults residing in rural areas experience the highest rates, with reporting chronic pain and reporting high-impact chronic pain.
Demographic variables such as advancing age, race, Hispanic origin, and biological sex significantly affect the statistical prevalence of self-reported chronic pain (Zelaya et al., 2020).
Economic Consequences:
The total cumulative financial burden—encompassing both direct medical expenses and indirect costs such as lost workplace productivity and absenteeism—arising from the use and misuse of alcohol, nicotine, and illicit drugs, combined with the misuse of prescribed prescription medications, surpasses annually (National Institute on Drug Abuse, 2020).
Multisystem Physiologic Sequelae of Unrelieved Pain:
Metabolic/Endocrine: Stress-induced release of catecholamines, cortisol, and glucagon leads to sustained hyperglycemia and catabolic state acceleration.
Cardiovascular: Sympathetic hyperactivity causes tachycardia, increased peripheral vascular resistance, elevated blood pressure, and markedly increased cardiac workload, which elevates myocardial oxygen consumption.
Immune System: Prolonged activation of neuroendocrine stress pathways precipitates immune system dysfunction, impairing immunocompetence and wound healing.
Hematologic: Neurohormonal stimulation induces hypercoagulability and altered coagulation profiles, increasing the vulnerability to deep vein thrombosis and thromboembolic events.
Gastrointestinal: Suppressed parasympathetic outflow combined with excessive sympathetic tone produces decreased gastrointestinal motility, resulting in paralytic gastrointestinal (GI) ileus, abdominal distension, nausea, and vomiting.
Renal/Genitourinary: Increased sphincter tone and detrusor hypomotility lead to acute urinary retention and secondary renal strain.
Respiratory: Splinting, muscle guarding, and restricted thoracic excursion result in decreased tidal volume and vital capacity, atelectasis, retention of tracheobronchial secretions, and elevated risk of pneumonia.
Musculoskeletal and General: Persistent muscular tension produces generalized muscle fatigue, muscle spasm, and physical exhaustion (Hinkle et al., 2022; Karch, 2020).
Psychosocial and Functional Burdens:
Patients experiencing unrelenting, inadequately managed pain frequently endure profound social isolation, physical disability, career stagnation, lost advancement, and structural changes in the distribution of household chores.
Interpersonal strain manifests as decreased marital and relationship satisfaction, substantial decrements in health-related quality of life, and pronounced limitations in completing complex instrumental activities of daily living (IADLs).
Psychological manifestations include severe fear, chronic anxiety, major depressive episodes, self-judgment, perceived pain invalidation by peers and clinicians, external stigmatization, and pervasive demoralization (Dahlhamer et al., 2018; Nicola et al., 2021; Suso-Ribera et al., 2020).
Regulatory Mandates and Institutional Standards
The Joint Commission Accreditation Mandates (Effective January 1, 2018):
Organizational Leadership Priority: Hospitals must formally designate pain assessment, individualized pain management, and safe opioid prescribing as primary organizational priorities. This requires forming an interprofessional leadership team, maintaining access to nonpharmacologic modalities, providing clinical staff and licensed independent practitioners with educational curricula and specialized consultation services, identifying accessible opioid treatment programs within the community, facilitating clinician and hospital pharmacist access to state Prescription Drug Monitoring Program (PDMP) databases, and procuring continuous technological monitoring devices for patients at high risk for opioid-related adverse outcomes (The Joint Commission, 2017, 2021).
Organized Medical Staff Engagement: Medical staff must actively fulfill leadership roles in organizational performance improvement (PI) initiatives. Responsibilities include co-authoring evidence-based pain management and opioid protocols, establishing meaningful clinical quality metrics, and systematically analyzing safety data.
Clinical Screening and Risk-Mitigated Management:
Hospitals must provide validated, readily accessible screening and assessment instruments suited to patient age, cognitive baseline, and clinical condition.
All patients must be systematically screened for pain during emergency department encounters and upon inpatient admission.
Clinical teams must treat pain directly or arrange formal transfers of care/referrals.
Individualized care plans must incorporate evidence-based practices, past medical history, pharmacological and nonpharmacological treatment modalities, and patient-specific comfort and functional goals.
Patients and families must be actively included in establishing realistic expectations, understanding the evaluation process, and participating in pain education.
Patients categorized as high-risk for opioid adverse events must undergo continuous physiological monitoring.
Care teams must reassess and document clinical responses according to established institutional timeframes, tracking progress toward functional goals, medication side effects, and risk factors for adverse events.
Comprehensive discharge planning must educate patients and caregivers on safe opioid storage, therapeutic use, side-effect recognition, activities of daily living modifications, and safe medication disposal methods (e.g., dedicated take-back programs or toilet flushing when authorized by federal guidelines).
Data Collection and Systematic Quality Improvement: Institutions are obligated to monitor performance data, evaluate intervention efficacy across varied populations, identify system vulnerabilities, and implement targeted adjustments to prevent medication errors and promote patient safety.
Conceptual Definitions and Theories of Pain
Classic and Contemporary Definitions:
Margo McCaffery Classic Definition (1968): "Pain is whatever the experiencing person says it is, existing whenever the experiencing person says it does." This foundational principle establishes that the experiencing individual is the ultimate and sole authority regarding the existence, intensity, and nature of their pain, requiring absolute clinician acceptance and validation.
International Association for the Study of Pain (IASP) Updated Definition (Raja et al., 2020): "An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage."
Core Interpretive Notes of the IASP Definition:
Pain is invariably a personal experience shaped to varying degrees by dynamic biological, psychological, and social interactions.
Pain and nociception represent distinct biological phenomena; subjective pain cannot be deduced or inferred solely from activity within sensory neural pathways.
Individuals acquire and internalize the conceptual understanding of pain throughout their unique life experiences.
A person's self-report of an experience as pain must be accepted, respected, and validated by healthcare providers.
Although pain typically serves an adaptive, protective evolutionary role, chronic or intractable pain frequently exerts destructive effects on functional ability and psychological and social well-being.
Verbal description represents merely one of several behavioral indicators of pain; the absence of verbal communication capacity never negates the possibility that a human or animal is experiencing pain.
Gate Control Theory of Pain (Melzack & Wall, 1965):
Core Neurobiological Mechanism: The gate control theory offers the primary practical model detailing the transmission, modulation, and central perception of noxious sensory input. Transmission of painful stimuli is modulated by a neural gating mechanism located primarily within the substantia gelatinosa cells of the dorsal horn in the spinal cord.
Small vs. Large Fiber Interaction:
Small-Diameter Nerve Fibers ( and fibers): Conduct excitatory, noxious stimuli toward the central nervous system. Activation of these small fibers acts via positive feedback to keep the spinal gate open, transmitting excitatory impulses toward the thalamus and cerebral cortex.
Large-Diameter Nerve Fibers ( fibers): Conduct non-noxious cutaneous sensations such as touch, pressure, vibration, and mild thermal stimulation. Activation of these large fibers stimulates inhibitory interneurons within the substantia gelatinosa, triggering a negative feedback mechanism that closes the spinal gate and inhibits upstream transmission of concurrent nociceptive impulses.
Sensory Processing Limits: The central nervous system possesses a finite capacity for processing sensory data simultaneously. When the spinal cord is overwhelmed by cutaneous non-nociceptive tactile signals, spinal gating cells block or interrupt nociceptive signals from traveling up the spinothalamic tracts.
Everyday and Clinical Gate-Closing Exemplars:
Vigorously rubbing an injured extremity immediately following an acute blunt impact stimulates large-diameter cutaneous fibers, diminishing the central perception of pain.
Targeted nursing interventions—such as effleurage back massage, superficial applications of warm or cold packs, and transcutaneous electrical nerve stimulation (TENS)—stimulate large-diameter sensory fibers to close the substantia gelatinosa gate.
Supraspinal and Psychosocial Gating Modulation: The spinal gate is also regulated by descending pathways from the brainstem and cerebral cortex. Cognitive, emotional, and psychological variables exert descending controls:
Gate-Closing Factors: Positive emotional affect, cognitive distraction, structured relaxation techniques, optimism, and guided imagery send descending inhibitory signals to close the gate.
Gate-Opening Factors: High anxiety, fear, anticipatory stress, catastrophic thinking, depression, boredom, and feelings of helplessness send descending facilitatory signals that open the gate, heightening pain intensity.
The Neurophysiology of Pain: The Nociceptive Process
Overview of Nociception: Nociception represents the physiologic process by which noxious tissue-damaging stimuli are detected and processed by an intact nervous system. It consists of four distinct, sequential phases: transduction, transmission, perception, and modulation.
1. Transduction:
Definition and Receptor Activation: Transduction is the biochemical conversion of noxious thermal, chemical, or mechanical energy into action potentials (electrical impulses) across peripheral somatosensory receptors known as nociceptors (undifferentiated free nerve endings).
Noxious Stimulus Types:
Mechanical Stimulants: Friction from rough bed linens, intense pressure from an excessively tight orthopedic cast, surgical incisions, or direct blunt trauma.
Thermal Stimulants: Extreme heat (e.g., contact burns, severe sunburn) or extreme cold (e.g., ice immersion, contact of cold liquids with dental caries).
Chemical Stimulants: Direct contact with strong external acids or alkalis, or internal accumulation of chemical mediators.
Electrical Stimulants: The shock of high-voltage wiring or high-intensity static discharges.
Biochemical Inflammatory Mediators: Injured cells and extravasated plasma components release a soup of chemical substances that activate or sensitize primary afferent nociceptors:
Bradykinin: A potent endogenous peptide vasodilator released immediately following tissue damage. It increases local capillary permeability, stimulates vascular smooth muscle constriction, directly triggers the release of histamine from mast cells, and produces the hallmark redness, edema, and intense throbbing pain of acute inflammation prior to the arrival of signals at the brain.
Prostaglandins: Lipid compounds synthesized via the cyclooxygenase (COX) enzyme pathway from arachidonic acid. They do not stimulate nociceptors directly, but lower the activation threshold of peripheral pain receptors, amplifying excitatory stimuli delivered to the CNS.
Substance P: An excitatory neuropeptide concentrated in primary afferent sensory neurons. It directly sensitizes peripheral nerve endings, mediates neurogenic inflammation, and accelerates the firing rates of post-synaptic neurons in the spinal cord.
Histamine: Released by mast cells in response to tissue disruption and bradykinin exposure, histamine stimulates cutaneous nociceptive endings, eliciting pain, pruritus, and localized vascular leakage.
Lactic Acid: Rapidly accumulates within hypoperfused or ischemic tissues due to anaerobic metabolism, drastically decreasing interstitial and exciting free nerve endings while lowering their activation thresholds to mechanical pressure and heat.
Serotonin (): A monoamine neurotransmitter and vascular agent that stimulates smooth muscle contraction, promotes vasoconstriction, and modulates excitatory or inhibitory actions across primary afferent synapses.
Peripheral Sensitization: Continuous, repetitive, or prolonged exposure of peripheral nociceptors to inflammatory mediators leads to sensitization: a state in which the activation threshold of nociceptors is significantly lowered. Consequently, even low-intensity, non-damaging mechanical or thermal stimuli elicit firing, and signals transmit with heightened frequency and perceived intensity.
2. Transmission:
Definition: Transmission involves the conduction of electrical impulses generated at the peripheral terminal along specialized sensory nerve pathways into the dorsal horn of the spinal cord, up ascending spinothalamic tracts, and ultimately to higher brainstem and cerebral centers.
Afferent Fiber Subtypes:
Fibers: Larger-diameter, thinly myelinated, rapidly conducting primary afferent fibers (conduction velocity up to ). They transmit sharp, acute, stinging, well-localized pain sensations typically provoked by acute mechanical or sharp thermal inputs (e.g., immediate pain from a sterile needle prick or scalpel cut).
Fibers: Small-diameter, unmyelinated, slowly conducting primary afferent fibers (conduction velocity approximately ). They transmit dull, aching, throbbing, diffuse, burning, and longer-lasting pain sensations provoked by persistent chemical exposure, tissue inflammation, or chronic mechanical trauma.
Protective Withdrawal Reflex Arc:
In addition to ascending central transmission, sensory afferent impulses carried by fibers pass through the dorsal root ganglion into the dorsal horn of the spinal cord.
Within the dorsal horn, the afferent axon synapses with an interneuron and directly activates a somatic motor neuron located in the anterior/ventral horn.
The motor impulse travels along efferent nerve pathways back to the effector muscles at the site of stimulation, initiating immediate, involuntary muscular contraction to withdraw the endangered tissue from the noxious stimulus (e.g., involuntarily jerking one's hand away from a burning hot stove burner).
Ascending Pathways:
Afferent nociceptive fibers synapse within the substantia gelatinosa of the dorsal horn.
Secondary neurons decussate (cross the midline) within the anterior spinal commissure and ascend via the anterolateral system (spinothalamic tracts).
The impulse terminates within the thalamus, the primary sensory relay station where sensations such as thermal changes, mechanical pressure, and coarse pain first enter conscious awareness.
Tertiary neurons project from the thalamus to the primary somatosensory cortex and limbic structures, facilitating conscious perception of the precise anatomical location, intensity, and sensory quality of the pain.
3. Perception:
Sensory Processing and Interpretation: Pain perception is the conscious awareness and subjective interpretation of nociceptive signals within the cerebral cortex, involving integration of sensory-discriminative, affective-motivational, and cognitive-evaluative dimensions.
Pain Threshold: The minimum intensity of a stimulus that is first perceived by an individual as painful (IASP, 2021). The sensory pain threshold remains relatively constant across human populations under standardized conditions, but psychological and physiologic states can shift it.
Sensory Adaptation: Prolonged exposure to non-damaging, gradual changes in sensory stimuli can induce accommodation. For example, if a person's hand is immersed in tepid water that is slowly heated, the individual can tolerate higher fluid temperatures before reporting pain than if the hand had been plunged abruptly into boiling water without preparatory grading.
4. Modulation:
Definition: The physiological process whereby nociceptive transmission within the nervous system is inhibited, dampened, or modified through endogenous neural circuits and biochemical substances.
Endogenous Neuromodulators: Naturally occurring, morphine-like endogenous opioid peptides synthesized within the spinal cord and brain. They bind stereospecifically to opioid receptor sites (, , ) distributed throughout the central and peripheral nervous systems, inhibiting the presynaptic release of excitatory neurotransmitters (such as substance P and glutamate) and hyperpolarizing postsynaptic membranes.
Major Classes of Neuromodulators:
Endorphins: Powerful endogenous opioid peptides synthesized at multiple neural synapses along the brainstem and hypothalamic-pituitary axis. They produce prolonged analgesia, promote vascular stability, and induce euphoria. Among all known endogenous endorphins, dynorphin possesses the most potent, concentrated analgesic properties.
Enkephalins: Widely distributed throughout the cerebral cortex, thalamus, and dorsal horns of the spinal cord. Although chemically less potent than dynorphins and beta-endorphins, enkephalins modulate pain by inhibiting the release of substance P from primary afferent terminals within the substantia gelatinosa.
Endogenous Activation: The endogenous opioid system is activated under conditions of intense physical exercise, severe acute trauma, high psychological stress, transcutaneous nerve stimulation, acupuncture, and structured relaxation exercises.
Classifications and Taxonomies of Pain
Classification by Duration:
Acute Pain:
Onset and Duration: Sudden or rapid in onset, varying in severity from mild to agonizing; typically lasts less than .
Clinical Purpose: Serves a protective biological function by alerting the organism to actual tissue damage or impending organic disease.
Physiologic Signs: Triggers intense sympathetic nervous system activity ("fight-or-flight" response), manifesting as transient tachycardia, tachypnea, peripheral vasoconstriction, diaphoresis, and hypertension.
Resolution: Resolves predictably as the underlying tissue trauma heals. Common causes include traumatic lacerations, bone fractures, acute pharyngitis, and surgical incisions.
Chronic Pain:
Onset and Duration: Maladaptive, non-protective pain that persists or recurs for longer than , extending well past normal physiological healing timelines.
Classification Subtypes (Treede et al., 2019):
Chronic Primary Pain: Pain represents the disease entity itself, lacking evidence of underlying systemic disease, structural damage, or distinct ongoing pathology. Examples include fibromyalgia, chronic nonspecific low back pain, and chronic primary headache.
Chronic Secondary Pain: Pain originates from an identifiable underlying disease state, categorized into chronic cancer-related pain, chronic postsurgical or posttraumatic pain, chronic neuropathic pain, chronic secondary headache or orofacial pain, chronic secondary visceral pain, and chronic secondary musculoskeletal pain.
Presentation Patterns: Presentation varies widely: continuous and unrelenting; episodic or recurrent with cyclical periods of remission (disease pathology remains present, but the individual experiences a temporary absence of pain) and exacerbation (symptoms acutely flare); or complex presentations blending persistent chronic pain with superimposed acute episodes.
Assessment Challenges: Chronic pain is frequently poorly localized and lacks consistent objective autonomic physical signs (due to autonomic adaptation), which can lead to skepticism and bias among healthcare providers.
Classification by Localization and Location:
Cutaneous (Superficial) Pain: Involves the epidermis, dermis, or immediate subcutaneous tissue. Manifests as sharp, burning, well-localized pain (e.g., a paper cut or superficial thermal burn).
Deep Somatic Pain: Diffuse, scattered pain originating in deeper anatomical structures including periosteum, tendons, ligaments, bones, skeletal muscle, deep blood vessels, and nerves. Elicited by strong localized pressure on bone, ischemic muscle contractions, or ligamentous tears (e.g., severe ankle sprains, bone fractures).
Visceral (Splanchnic) Pain:
Origins: Originates in internal body organs located within the cranium, thorax, and abdominal cavities.
Mechanisms: Triggered by acute stretching of hollow viscous walls, organ distension, smooth muscle spasm, capsular traction, ischemia, or severe internal inflammation (e.g., pancreatitis, cholecystitis, bowel obstruction).
Guarding: Severe acute visceral pain triggers a protective involuntary reflex contraction and rigidity of the overlying abdominal wall muscles, known as guarding, designed to shield underlying inflamed structures from physical palpation or external trauma.
Referred Pain:
Pain perceived at an anatomical site distant from its actual point of origin, but innervated by the same spinal cord segments.
Pathophysiologic Basis: Convergence of visceral and somatic sensory afferent fibers onto the same second-order dorsal horn projection neurons in the spinothalamic tract.
Clinical Exemplar: Acute myocardial infarction typically refers nociceptive pain to the neck, jaw, interscapular back, left shoulder, and inner aspect of the left arm.
Classification by Etiologic Mechanism:
Nociceptive Pain: Normal physiological pain arising from actual or threatened damage to non-neural tissue, initiated by appropriate activation of peripheral nociceptors.
Neuropathic Pain:
Definition: Pain caused by a direct lesion, injury, or disease affecting the peripheral or central somatosensory nervous system (IASP, 2021; Raja et al., 2020).
Clinical Descriptors: Characterized as lancinating, stabbing, electric shocks, hot burning, searing, tingling, or crawling sensations (paresthesias).
Associated Neuropathic Phenomena:
Allodynia: An unexpected, abnormal pain response elicited by an innocuous stimulus that does not normally provoke pain (such as the light brushing of a cotton sheet across the skin).
Hyperalgesia: An abnormally exaggerated, increased pain response to a stimulus that is normally mildly painful.
Hyperesthesia: An increased, heightened sensitivity to any cutaneous sensory stimulation.
Nociplastic Pain: Mechanistically distinct pain that arises from altered nociceptive processing (central sensitization, augmented central processing, or deficient descending modulation) despite no clear biological evidence of actual or threatened tissue damage activating peripheral nociceptors, nor disease/lesion of the somatosensory nervous system (e.g., fibromyalgia).
Intractable Pain: Persistent pain that is wholly resistant and refractory to conventional pharmacological, nonpharmacological, and interventional pain management strategies.
Phantom Limb Pain: Neuropathic sensation and severe pain perceived in an amputated limb (either surgically or traumatically lost). Manifests as crushing, burning, fiery, twisting, or distorted sensations. Arises in the absence of peripheral receptors due to persistent neuroplastic sensory representations (cortical reorganization and central memory traces) remaining within the cerebral somatosensory cortex.
Specific Common Neuropathic Pain Syndromes:
Complex Regional Pain Syndrome (CRPS / Causalgia): Occurs following partial traumatic injury to a major peripheral nerve (most commonly the median nerve, sciatic nerve, or brachial plexus). Characterized by severe, burning, diffuse, intractable pain elicited by minimal cutaneous touch or joint movement, progressively worsening with repeated stimulation and continuing long after stimulation ends. Accompanied by localized edema, vasomotor instability, sudomotor changes, and trophic skin alterations.
Postherpetic Neuralgia: Neuropathic complication following acute reactivation of the varicella-zoster virus (shingles) within dorsal root ganglia. Characterized by severe, burning, unilateral, dermatomic neuralgic pain arrayed in band-like clusters along infected nerve roots; can remain intractable for months or years following the resolution of vesicular skin lesions.
Trigeminal Neuralgia (Tic Douloureux): Paroxysmal neurovascular compression or demyelination involving one or more branches of the fifth cranial nerve (). Manifests as sudden, violent, shock-like, unilateral facial pain lasting seconds to minutes across the lips, gums, cheek, chin, and orbit, triggered by innocuous mechanical stimuli such as chewing, talking, shaving, light breezes, or brushing teeth.
Diabetic Neuropathy: Symmetric distal sensorimotor polyneuropathy resulting from chronic hyperglycemia, microvascular ischemic angiopathy, and metabolic nerve fiber injury. Early symptoms feature burning paresthesias, prickling, and numbness in a "glove-and-stocking" distribution. Progressive sensory loss eliminates protective sensation, exposing extremities to unperceived trauma, chronic neuropathic ulceration, secondary osteomyelitis, and gangrene.
Responses to Pain: Behavioral, Physiologic, and Affective
Behavioral (Voluntary) Responses:
Moving or pulling away from painful stimuli.
Facial expressions: grimacing, wincing, frowning, clenching the jaw, or tightly closing the eyes.
Vocalizations: moaning, crying, groaning, screaming, or whimpering.
Motor behaviors: restlessness, pacing, thrashing, rocking, or protecting and bracing the painful anatomical area (guarding and refusing to move).
Physiologic (Involuntary) Responses:
Sympathetic Responses (Prevalent in Superficial and Moderate Pain):
Elevation of arterial blood pressure.
Tachycardia (increased pulse rate) and tachypnea (increased respiratory rate).
Pupillary dilation (mydriasis).
Increased skeletal muscle tension and generalized rigidity.
Cutaneous pallor due to peripheral arteriolar vasoconstriction.
Increased adrenal epinephrine and norepinephrine output.
Hepatic glycogenolysis leading to elevated blood glucose levels.
Vital Sign Caveat: Sympathetic elevations may manifest transiently in acute pain states, but normalize over time due to neurohormonal adaptation; they are typically absent in chronic pain states.
Parasympathetic Responses (Prevalent in Severe, Deep Somatic, or Visceral Pain):
Nausea, retching, and active vomiting.
Syncope, vasovagal fainting, or loss of consciousness.
Hypotension (decreased blood pressure).
Bradycardia (decreased pulse rate).
Prostration, extreme pallor, and diaphoresis.
Rapid, irregular, shallow breathing patterns.
Affective (Psychological) Responses:
Exaggerated weeping, emotional agitation, and restlessness.
Social withdrawal and communicative detachment.
Stoicism and suppression of distress.
Generalized anxiety, panic, and catastrophic worry.
Major depression, hopelessness, and demoralization.
Intense fear regarding bodily integrity or terminal illness.
Irritability, agitation, hostility, and anger.
Anorexia and progressive loss of appetite.
Physical, mental, and emotional fatigue.
Insomnia, fragmented sleep architecture, and exhaustion.
Perceptions of powerlessness, loss of autonomy, and alienation.
Biopsychosocial and Cultural Factors Influencing the Pain Experience
The Biopsychosocial Model of Pain (Engel, 1977):
Extends the mechanistic biomedical paradigm into an integrated framework that analyzes pain and suffering across three interdependent domains:
Biological Components: Genetic variations (e.g., mu-receptor polymorphism, drug-metabolizing enzymes), anatomical injuries, physiological stress reactivity, age-related functional status, and biological sex.
Psychological Components: Personality structures, cognitive appraisal, past pain trauma, psychiatric comorbidities (anxiety, depression), perceived control, coping repertoires, and health literacy.
Social Components: Cultural traditions, primary family dynamics, socioeconomic position, employment status, systemic inequities, healthcare access, and the physical environment.
Clinical Terminology for Describing Pain Characteristics:
Quality:
Sharp: Stabbing, piercing, knife-like, and intense.
Dull: Less localized and less intense than sharp pain; persistent, heavy, aching, and annoying.
Diffuse: Encompasses a large, non-demarcated area where the patient is unable to point to a discrete location without moving an entire hand across a broad surface.
Shifting: Migrates dynamically from one anatomical zone to another (e.g., radiating from the hypogastrium to the epigastrium).
Additional Descriptors: Sore, stinging, pinching, cramping, gnawing, cutting, throbbing, shooting, and vise-like pressure.
Severity (Intensity) on a Standardized Scale:
Slight / Mild Pain: Rated between and .
Moderate Pain: Rated between and .
Severe / Excruciating Pain: Rated between and .
Periodicity:
Continuous: Unremitting pain that never fully stops.
Intermittent: Pain that ceases and restarts at intervals.
Brief or Transient: Intermittent sensations that appear and resolve rapidly.
Cultural and Ethnic Variables:
Cultural backgrounds deeply influence individual cognitive appraisal, verbal disclosure, and behavioral expressions of pain. In some cultures, stoicism and enduring pain in silence are revered as demonstrations of character, dignity, and spiritual strength; in others, open vocalization, intense crying, and demanding pain interventions are normative social expectations (Cancio, 2020; Purnell, 2013).
Nurses must practice cultural humility, avoiding ethnic stereotypes and recognizing that individuals of similar ethnic backgrounds display divergent responses.
Demographic Projections: By the year , over half of all United States residents are projected to belong to minority demographic populations, with the non-Hispanic White population dropping to (Colby & Ortman, 2015). This expanding diversity increases the probability of linguistic discordant encounters.
Linguistic Nuances and Barriers: Critical differences exist between semantic terms across languages and dialects (e.g., distinguishing between a mild "ache" and severe "pain"). Communication barriers directly correlate with undertreated, poorly controlled pain. Professional medical interpreters and multilingual validated tools are required.
Social Determinants and Health Disparities: Low-income populations (Newman et al., 2018) and racial/ethnic minority patients systematically receive less aggressive, lower-quality pain care and face documented prescribing disparities in acute and chronic settings (Beletsky et al., 2021; Kim et al., 2020). Minority patients experience pain for longer periods before presentation, encounter systematic bias, and face structural barriers in rural and urban regions.
Family, Sex, Gender, and Age Considerations:
Family Influences: Early family socialization teaches individuals whether pain should be stoically suppressed, openly expressed, or leveraged for caretaking attention. Family size and birth order do not significantly correlate with adult chronic pain susceptibility.
Sex and Gender: Societal gender role expectations shape pain tolerance and reporting (e.g., historical socialization discouraging boys from crying). Women report chronic pain more frequently than men, exhibit lower thresholds to experimental pain stimuli, and communicate discomfort more readily. However, healthcare providers often misattribute women's pain to emotional or psychosomatic etiologies (American Society of Anesthesiologists, 2016).
Age and Developmental Stages:
Infants and Children: Historical beliefs that neonates could not perceive pain due to immature myelin development are incorrect; neonates, including premature infants, experience acute sensitivity to noxious inputs.
Older Adults: Up to of community-dwelling older adults and over of nursing home residents endure daily pain (Galicia-Castillo & Weiner, 2021). Pain is not a normal physiological consequence of aging. Misconceptions among providers, combined with fears among older adults that reporting pain signifies impending death or terminal illness, lead to widespread undertreatment.
Religious Beliefs and Spirituality:
Religious doctrines interpret pain along divergent philosophical axes: some patients view suffering as an opportunity for spiritual purification, penance, or divine identification, choosing to decline analgesics to offer their pain for sins. Conversely, others interpret unremitting pain as divine punishment or abandonment by God, precipitating existential crises, anger, and loss of faith (Matteliano et al., 2014).
Environmental Factors and Secondary Gains:
Sensory overload in intensive care units (continuous monitor alarms, bright lights, fragmented sleep) amplifies pain perception. Depersonalization and separation from familiar comfort items or emotional support networks intensify discomfort.
Some individuals use persistent pain to elicit secondary gains (such as focused family attention, emotional service, or relief from societal duties). If left unaddressed, secondary gains can breed family resentment, caregiver fatigue, and behavioral avoidance.
Fatigue, Anxiety, and Past Pain History:
Anxiety and fear of the unknown heighten muscle tension and augment central pain perception. Physical and mental exhaustion depletes emotional coping reserves, lowering pain tolerance.
Individuals who have experienced severe pain without receiving adequate relief develop heightened anticipatory anxiety, hypervigilance, and catastrophic reactions to subsequent pain encounters.
Pain Assessment: Routine Screening and Validated Tools
Routine Pain Assessment and Evolution of Clinical Guidelines:
In 1995, the American Pain Society introduced the concept of assessing pain as the "fifth vital sign" to elevate pain awareness and management. However, this policy unintentionally resulted in mandatory numeric scoring linked mechanically to every vital sign check, driving aggressive, reflexive opioid overprescribing.
The Joint Commission eliminated the "fifth vital sign" terminology from its accreditation standards in 2004 (Baker, 2017). Current standards emphasize individualized, comprehensive assessments that evaluate functional outcomes, realistic comfort goals, and the systematic mitigation of opioid-related risks.
Common Patient Misconceptions Hindering Assessment:
Belief that physicians prescribe all required medications routinely, requiring no self-report.
Fear that requesting any analgesic will lead immediately to drug addiction.
Belief that enduring excruciating pain is preferable to managing analgesic side effects.
Belief that talking about pain is childish or a sign of weakness.
Conviction that one must wait until pain becomes severe before requesting analgesia, under the mistaken belief that early medication will lose efficacy.
Reluctance to "bother" busy nurses and physicians.
Acceptance of excruciating postoperative pain as inevitable.
Core Components of a Comprehensive Pain Assessment:
Direct patient verbal self-report (the clinical gold standard).
Onset and precise etiology/mechanism of injury.
Duration, temporal patterns, and periodicity.
Anatomical location, distribution, and patterns of radiation.
Quality, character, and descriptive terminology.
Intensity and severity scored on a validated scale.
Aggravating and precipitating triggers.
Alleviating and relieving measures.
Associated psychological, affective, and cognitive symptoms (anxiety, depression, insomnia).
Impact on activities of daily living (mobility, hygiene, occupational performance, mood).
Establishment of a mutually agreed-upon, realistic numeric pain management goal.
Comprehensive Inventory of Standardized Pain Rating Scales:
0–10 Numeric Rating Scale (NRS): Standard horizontal scale where represents "no pain" and represents "worst pain imaginable." Indicated for adults and verbally proficient children older than across all care settings.
Wong–Baker FACES Pain Rating Scale: Visual scale displaying six drawn faces ranging from a smiling, happy face () to a crying, grimacing face (). Indicated for children aged and older, as well as adult patients with language barriers or mild cognitive deficits.
Faces Pain Scale–Revised (FPS-R): Depicts six gender-neutral, non-smiling cartoon facial expressions scored () without tear depictions, preventing confounding between sorrow and physical nociception. Validated for children aged .
Oucher Pain Scale (Beyer et al., 1992): Combines a vertical numeric scale for older children with a photographic gradient of six real children's faces demonstrating ascending levels of physical distress. Culturally adapted versions feature photographic series representing diverse ethnic and racial groups.
FLACC Behavioral Scale (Face, Legs, Activity, Cry, Consolability): Observational behavioral scoring system evaluating five parameters scored from , yielding a cumulative score between and . Validated for infants and children aged , and nonverbal or cognitively impaired pediatric and adult patients.
CRIES Instrument: Postoperative pain scale for neonates and infants aged . Evaluates: Crying (characteristic high-pitched), Requires for saturation , Increased vital signs (heart rate and blood pressure above baseline), Expression (facial grimace), and Sleeplessness.
COMFORT Behavior Scale: Complex behavioral assessment evaluating six behavioral domains (alertness, calmness, respiratory response or crying, physical movement, muscle tone, facial tension) and two physiologic parameters (mean arterial pressure and heart rate baselines). Validated for critically ill, ventilated, and nonverbal pediatric and adult populations.
Adult Nonverbal Pain Scale (NVPS): Evaluates nonverbal indicators across five categories: facial expression, activity/movement, guarding, physiologic indicators (vital signs), and respiratory effort. Indicated for sedated, unresponsive, or critically ill adult patients.
Checklist of Nonverbal Indicators (CNPI): Measures six nonverbal behaviors: vocal complaints (nonverbal), vocal complaints (verbal), facial grimaces/winces, bracing, restlessness, and rubbing. Scored at rest and during movement for adults with cognitive impairment unable to use standard self-report scales.
Behavioral Pain Scale (BPS): Assesses three observational dimensions: facial expression, upper limb movements, and compliance with mechanical ventilation. Validated for intubated, critically ill intensive care unit patients.
Critical-Care Pain Observation Tool (CPOT): Evaluates four behavioral categories: facial expression, body movements, muscle tension (evaluated by passive flexion/extension of an extremity), and ventilator compliance (or vocalization in extubated patients). Indicated for sedated, critically ill adults.
Iowa Pain Thermometer (IPT) and Revised IPT (IPT-R): A vertical thermometer-shaped visual scale featuring descriptive verbal anchors and color gradients. Highly preferred by older adults, especially those experiencing mild-to-moderate cognitive or visual impairments, over horizontal numeric scales.
Pain Assessment in Advanced Dementia (PAINAD) Scale (Warden et al., 2003): An observational assessment tool designed for patients with advanced dementia who cannot communicate verbally. Evaluates five distinct items: breathing (independent of vocalization), negative vocalization, facial expression, body language, and consolability (each scored , producing a total between ).
Pain Assessment in Specialized and Vulnerable Populations
Pediatric Pain Assessment:
Pediatric pain requires a multimodal assessment strategy integrating a targeted pain history, developmental level appraisal, systematic parent/guardian interviews, and structured behavioral observation.
Behavioral Indicators of Pediatric Distress: Persistent irritability, inconsolable crying, shrill vocal screaming, grimacing, teeth grinding, tight hand clenching, direct grabbing or pointing to painful body sites, and aggressive motor defense (kicking, thrashing, or actively pulling away).
Direct child self-report represents the most valid and reliable single metric when developmentally possible. Clinical tools must match developmental age (e.g., CRIES for neonates, FLACC for young children, FACES for early childhood, and Oucher or NRS for older children).
Patients with Cognitive Impairment:
Cognitively impaired individuals—including residents of long-term care facilities with Alzheimer disease or vascular dementia—are at high risk for undertreated pain.
Chronic unmanaged pain accelerates neurocognitive decline and memory degradation in older populations (van der Leeuw et al., 2018).
Observable Indicators of Pain in Nonverbal Dementia: Rapid onset of agitation, unprovoked physical aggression, sudden changes in interpersonal social interactions, disruptions in established eating or sleeping patterns, wandering, furrowed brow, pacing, vocalized moaning, or sudden physiological deterioration.
Clinicians must combine validated observational tools (e.g., PAINAD, CNPI) with direct proxy reports from primary family members and regular nursing home caregivers.
Community-Dwelling and Institutionalized Older Adults:
Pathophysiologic Considerations: Age-related physiological decline alters nociceptive processing and substantially alters drug pharmacokinetics (decreased glomerular filtration rates, decreased hepatic blood flow, reduced cytochrome P450 enzyme activity) and pharmacodynamics (increased central nervous system sensitivity).
Assessment Modifications: Providers must account for sensory deficits (presbyopia, presbycusis), utilize vertical visual formats (e.g., IPT-R), use clear open-ended questions, allow sufficient time for cognitive processing, and cross-reference extensive polypharmacy profiles for drug-drug interactions.
Critically Ill Intensive Care Unit (ICU) Patients:
Severe pain occurs frequently at rest, during routine hygiene care (repositioning, endotracheal suctioning, dressing changes), and following invasive procedures.
Clinical practice guidelines require systematic assessment using validated observational tools (BPS or CPOT). Clinicians must treat pain aggressively before initiating or increasing sedative infusions (Devlin et al., 2018).
Nursing Diagnoses, Planning, and Care Management
Diagnostic Classification:
Pain as the Primary Problem Statement:
Acute Pain: Related to physical injury agents (e.g., tissue trauma from surgical incision, burn injury, bone fractures, sickle cell vaso-occlusive crisis). Manifested by verbal self-report of pain on standardized scales, wincing, facial grimacing, motor guarding, diaphoresis, and transient elevations in heart rate and blood pressure.
Chronic Pain: Related to prolonged musculoskeletal injury, neuropathic damage, or central nociplastic amplification (e.g., post-laminectomy syndrome, diabetic neuropathy, fibromyalgia). Manifested by self-report of continuous or recurrent pain persisting longer than , altered functional status, sleep disturbance, anorexia, depression, and social withdrawal.
Difficulty Coping with Pain: Related to inadequate pain control, fear of opioid addiction, exhaustion, lack of social support systems, or stigma. Manifested by expressions of despair, reluctance to engage in prescribed therapy, and decline in self-care abilities.
Pain as the Underlying Etiology:
Ineffective Airway Clearance: Related to reluctance to cough, deep breathe, or ambulate secondary to severe postoperative subcostal incisional pain.
Constipation: Related to delayed gastrointestinal motility secondary to chronic scheduled opioid therapy and decreased mobility.
Acute Anxiety: Related to anticipation of pain and traumatic memories of unrelieved pain during prior procedures.
Altered Health Maintenance: Related to physical exhaustion and loss of motivation secondary to unrelenting chronic pain.
Sleep Deprivation: Related to nocturnal pain exacerbation and inability to achieve restorative non-REM/REM sleep cycles.
Risk for Self-Harm: Related to feelings of hopelessness, severe demoralization, and perceived loss of meaning in life secondary to unmanaged intractable pain.
Outcome Identification and Care Planning:
Acute Pain Patient Outcomes:
The patient will demonstrate a gradual reduction in pain intensity, documenting numeric scores meeting their established target goal (e.g., maintaining pain on a scale).
The patient will demonstrate proficient execution of the multi-modal pain management regimen, successfully engaging in early ambulation, incentive spirometry, and wound care.
Chronic Pain Patient Outcomes:
The patient will identify and access specialized interprofessional outpatient pain management clinics or community-based multidisciplinary support resources.
The patient will implement an individualized self-management regimen integrating complementary modalities, demonstrating measurable improvements in sleep, functional mobility, and completion of activities of daily living.
Clinical Exemplars and Reflective Practice
Pediatric Acute Pain Advocacy (The Exemplar of Xavier Malton):
Clinical Scenario: A 5-year-old pediatric patient diagnosed with ulcerative colitis (UC)—a chronic inflammatory bowel disease—suddenly triggered the bathroom emergency alarm toward the end of a shift. The patient was found doubled over in severe abdominal agony on the toilet, screaming that his abdomen was "hurting really, really bad," physically unable to stand or walk.
Clinical Advocacy and Systems Barriers: Review of the medical record revealed no active PRN orders for analgesic medication. The attending provider initially resisted prescribing any systemic analgesia, citing the commonality of pain in UC and recommending nonpharmacologic distraction. Drawing from personal clinical knowledge of inflammatory bowel pain, the nursing student and staff nurse advocated for the patient, securing an initial low-dose analgesic prescription. Because the initial dose proved completely inadequate (leaving the child curled in a fetal position screaming across the hallway), the nurses persistently followed the provider for beyond their scheduled shift to demand a comprehensive physical reassessment and a prescription for a systemic narcotic. When the ordered narcotic was found to be in hospital-wide short supply, the nurses spent an additional locating the medication from another unit.
Clinical Outcome: The narcotic was administered approximately after the nurses' shift had officially ended, successfully alleviating the child's pain and allowing him to sleep peacefully. This case demonstrates that professional nurse advocacy requires clinical persistence and challenging team members when care is inadequate (Tracey Sara Miller, Georgetown University).
Holistic Presence and Emotional Pain (The Exemplar of Bob):
Clinical Scenario: An adult male patient hospitalized with advanced cancer maintained a cheerful, smiling demeanor in the presence of business colleagues, visiting civic leaders, and his family. He consistently masked his terror regarding pain and death behind humor and stoicism, believing that "men aren't supposed to cry."
Nursing Intervention: Recognizing the patient's hidden distress after visitors departed, an observant nurse quietly placed her arm around his shoulders and whispered, "You know, Bob, it's all right to cry." This intervention dissolved his emotional defenses, allowing him to express his fears of dying, losing physical control, and burdening his family while the nurse provided silent presence and emotional support.
Chronic Pain and Diagnostic Delay (The Exemplar of Jennifer Tyler):
Clinical Scenario: A 44-year-old female patient presented with widespread body aching persisting for , severe morning fatigue, cognitive dysfunction ("brain fog"), insomnia, leg spasms, right shoulder pain, and debilitating lower back pain. She had previously self-medicated with over-the-counter ibuprofen and expired muscle relaxants, and had tried prescribed antidepressants and sedatives without relief.
Interprofessional Plan: Following extensive diagnostic laboratory workups to rule out alternative rheumatologic conditions, the primary provider suspected fibromyalgia and initiated treatment with pregabalin (Lyrica)—the first FDA-approved therapeutic agent for fibromyalgia. Nursing priorities focused on health literacy: educating the patient regarding gradual medication titration, advising about adverse side effects (dizziness, somnolence, blurred vision), emphasizing total avoidance of alcohol and central nervous system depressants, explaining the rationale for progressive physical therapy, and preparing her to ask structured questions at follow-up.
Postoperative Assessment and PCA Hesitancy (The Exemplar of Sheree Lincoln):
Clinical Scenario: An adult patient recovering from major abdominal surgery experienced an evolution from diffuse preoperative visceral pain to acute, localized deep somatic and incisional pain postoperatively. Despite reporting persistent surgical pain after surgery, the patient had not activated her Patient-Controlled Analgesia (PCA) pump.
Nursing Assessment and Action: The nurse investigated the root causes of the patient's reluctance, assessing for gaps in preoperative education, unfounded fears of immediate drug addiction, and fears of drug overdose. The nurse then re-educated the patient on the pump's safety lockout intervals, explained the physiological value of adequate pain control for respiratory recovery, and paired PCA use with nonpharmacologic repositioning.
Nonpharmacologic and Complementary Health Approaches (CHA)
Mechanisms and Indications of Complementary Modalities: Nonpharmacologic interventions serve as essential components of multimodal analgesia. They alter central pain processing, trigger descending inhibitory pathways, stimulate large-diameter afferent fibers to close spinal gates, and reduce autonomic hyperarousal without risking chemical adverse effects.
Distraction Techniques:
Neurophysiological Basis: Directing focused attention away from noxious sensations prevents cortical processing of pain signals, as sensory capacity within the reticular activating system and cerebral cortex is limited.
Timing: Most effective when implemented preemptively before a painful event occurs or immediately at onset; highly useful when paired with analgesics for acute procedural pain.
Categories of Distraction:
Visual: Counting environmental features, reading literature, or viewing television programs.
Auditory: Listening to structured acoustic playlists or ambient environmental sounds.
Tactile-Kinesthetic: Stroking a therapy animal, holding hands with a support person, rocking, playing with a soft toy, or pacing breathing.
Cognitive/Project: Engaging in interactive video gaming, complex puzzles, or occupational tasks.
Therapeutic Humor and Laughter:
Humor can serve as an effective cognitive distractor and coping mechanism during acute, procedural pain in responsive individuals, though it is never a substitute for pharmacological analgesia in moderate-to-severe pain.
Documented Systemic Physiologic and Psychological Effects (Box 36-2):
Directly elevates sensory and pain tolerance thresholds.
Reduces arterial wall stiffness and improves peripheral vascular endothelial function.
Reduces the overall incidence of acute myocardial infarction (MI) and decreases recurrent post-MI cardiac events in diabetic populations.
Improves pulmonary mechanics and ventilatory parameters in patients with chronic obstructive pulmonary disease (COPD).
Improves glycemic regulation and metabolic balance in metabolic syndrome and obesity.
Significantly increases the clinical success rate of in vitro fertilization (IVF) embryo transfers.
Promotes emotional well-being, psychological resilience, and overall quality of life (Ferner & Aronson, 2013; Noureldein & Eid, 2018).
Music Interventions:
Neurochemical Actions: Attenuates neuroendocrine stress responses by decreasing systemic circulating cortisol concentrations, reducing serum catecholamines (epinephrine and norepinephrine), and modulating inflammatory cytokine activity (specifically downregulating interleukin-6 [IL-6]).
Clinical Guidelines for Perioperative Practice: Music therapy reduces postoperative pain intensity, anxiety scores, and systemic opioid consumption (Hole et al., 2015; Kühlmann et al., 2018). Guidelines recommend playing calming music characterized by a steady tempo of continuously throughout surgical procedures, and for at least twice daily during pre- and postoperative periods (Poulsen & Coto, 2018).
Guided Imagery and Virtual Reality (VR):
Guided Imagery: Involves purposeful concentration on vivid mental images incorporating all sensory modalities (sight, sound, scent, touch). Patients focus internally on a tranquil scene, mobilizing personal psychological coping mechanisms and visualizing healing energies counteracting noxious foci. Effective in chronic pain management and procedural anxiety reduction.
Virtual Reality (VR): Immersive technology using head-mounted displays (HMDs) that visually and auditorily immerses patients within computer-generated three-dimensional environments, generating powerful cognitive distraction for severe acute burn wound care and complex procedural interventions (Chuan et al., 2021).
Mindfulness and Cognitive Behavioral Approaches:
Mindfulness-Based Stress Reduction (MBSR): Developed by Dr. Jon Kabat-Zinn in 1982 to facilitate chronic pain coping through nonjudgmental awareness, mindful breathing, open sensory acceptance, and seated meditation.
MBSR vs. Relaxation Techniques: Mindfulness practices emphasize nonjudgmental acceptance of immediate sensory and psychological experiences, whereas structured relaxation exercises actively aim to modify internal physiology (reducing heart rate, relaxing skeletal muscle tone; Luberto et al., 2020).
Cognitive Behavioral Therapy (CBT): Focuses on identifying and reframing maladaptive, catastrophic thought patterns and beliefs regarding pain, resolving functional problems, and encouraging progressive re-engagement in daily activities.
Nurse-Led CBT Evidence: An open randomized controlled trial evaluated an advanced practice registered nurse (APRN)-led intervention in with chronic nonmalignant pain. The protocol (one individual session followed by six weekly group sessions) produced sustained improvements in health-related quality of life, along with significant reductions in pain, anxiety, and depression at (Morales-Fernández et al., 2021).
Cutaneous Stimulation Modalities:
Therapeutic Massage: Effleurage, petrissage, and deep tissue manipulation stimulate cutaneous large-diameter nerve fibers, promote localized muscle relaxation, increase local blood flow, and close spinal gates.
Thermal Therapy: Superficial applications of localized heat (vasodilation, reduced muscle spasm) or cold (vasoconstriction, decreased tissue edema, slowed neural conduction velocity).
Acupressure: Manual application of firm fingertip pressure upon designated traditional Chinese medicine acupuncture points, promoting local comfort and endogenous endorphin release.
Clinical Evidence for Acupressure: Systematic reviews evaluate the stimulation of the P6 (Neiguan) acupressure point (located three finger-breadths proximal to the distal wrist crease between the flexor carpi radialis and palmaris longus tendons) to depress the hyperactive pharyngeal gag reflex during distressing pediatric and adult dental procedures (Eachempati et al., 2019).
Transcutaneous Electrical Nerve Stimulation (TENS): Noninvasive medical device delivering low-voltage electrical currents via cutaneous electrode pads positioned over or adjacent to painful sites. TENS selectively stimulates large-diameter sensory fibers, blocking upstream nociceptive transmission across the dorsal horn. Prescribed for acute postoperative incisional recovery, acute trauma, and chronic low back pain.
Electrical Muscle Stimulation (EMS / NMES / FES): Neuromuscular electrical stimulation delivers electrical pulses that induce visible skeletal muscle contractions to restore muscle strength, reduce atrophy, and alleviate secondary musculoskeletal spasms during physical rehabilitation.
Acupuncture and Trigger Point Dry Needling:
Acupuncture: Traditional Chinese medicine practice involving insertion of sterile, fine-gauge metallic needles into precise anatomical loci along systemic energy meridians to balance the flow of energy (chi) and trigger endogenous opioid release. Extensively utilized for chronic spinal pain, migraines, and osteoarthritis.
Trigger Point Dry Needling (TDN): Western anatomical intervention utilized by physical and occupational therapists. Sterile filiform needles are inserted directly into hyperirritable taut bands of skeletal muscle (myofascial trigger points) to release muscular contractures, alleviate referred pain, and normalize motor function (Bynum et al., 2021).
Hypnosis, Biofeedback, and Energetic Therapies:
Hypnosis and Autohypnosis: Hypnotic induction produces an altered state of focused consciousness and heightened suggestibility, altering cognitive perception of pain and associated autonomic reactivity.
Biofeedback: Uses electromyographic (EMG), galvanic skin, or skin-temperature sensors to provide continuous visual or auditory displays of autonomic responses (blood pressure, muscle tension). Patients learn conscious, voluntary self-regulation of involuntary physiologic processes (Wagner et al., 2021).
Healing Touch (HT) and Therapeutic Touch (TT): Biofield energy therapies developed by nurses. Healing Touch incorporates gentle, light physical contact to balance human energetic fields. In contrast, Therapeutic Touch (TT) uses a non-contact technique where the practitioner's hands are moved above the patient's body surface to smooth energy disruptions, providing comfort in palliative and terminal care (Tabatabaee et al., 2016; Weaver, 2017).
Animal-Assisted Interventions (AAI / AAA): Structured interactions with trained therapy animals (dogs, cats, rabbits, guinea pigs, birds, llamas; Pet Partners) that lower distress, reduce perceived pain, and facilitate mobility in pediatric and adult settings. Robotic pet interventions (PRI) provide similar emotional benefits for institutionalized patients with advanced dementia without hygiene concerns (Park et al., 2020).
Pharmacologic Management: Nonopioids, Opioids, and Adjuvants
Three Classes of Analgesics: Pharmacologic pain management relies on three overarching drug categories: nonopioid analgesics, opioid analgesics, and adjuvant analgesics.
Nonopioid Analgesics:
Acetaminophen:
Mechanism and Indications: Acts primarily within the central nervous system to inhibit prostaglandin synthesis, providing analgesic and antipyretic effects without peripheral anti-inflammatory action or platelet disruption.
Dosing Safety: Widely utilized as first-line therapy for mild-to-moderate acute pain and osteoarthritis. Maximum recommended daily dose is () in healthy adults; excessive dosing carries severe risks of fatal hepatotoxicity.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
Mechanism: Competitively inhibit the cyclooxygenase (COX) enzyme, suppressing the conversion of arachidonic acid into pro-inflammatory prostaglandins and thromboxanes.
Black Box Warnings and Contraindications: Contraindicated in patients with active peptic ulcer disease, bleeding disorders, and severe renal impairment. Contraindicated during pregnancy at gestation or later due to risks of fetal renal dysfunction and oligohydramnios (FDA, 2020b). The FDA mandates black box warnings detailing risks for severe gastrointestinal bleeding, ulceration, and perforation, as well as an increased risk for serious thrombotic cardiovascular events, myocardial infarction, and fatal stroke for all NSAIDs except aspirin.
Selective COX-2 Inhibitors: Agents like celecoxib specifically inhibit the inducible COX-2 enzyme, providing anti-inflammatory relief with reduced gastrointestinal mucosal toxicity, though they carry elevated cardiovascular thrombotic risks.
Opioid Analgesics:
Receptor Pharmacology:
Mu () Receptors: Primary targets for clinical opioid analgesia. Activation induces profound analgesia, respiratory depression, euphoria, miosis (pupillary constriction), suppressed gastrointestinal motility (leading to constipation), and physical dependence.
Delta () Receptors: Distributed along peripheral terminals and spinal pathways, modulating localized antinociception.
Kappa () Receptors: Mediate spinal and supraspinal analgesia, accompanied by pupillary changes, sedation, and dysphoria (feelings of deep unease, restlessness, and anxiety).
Agonists vs. Antagonists: Pure agonists (e.g., morphine, hydromorphone, fentanyl) bind to and activate mu receptors to provide analgesia. Pure antagonists (e.g., naloxone) bind competitively to mu receptors without activating them, displacing agonists and reversing both analgesia and adverse effects.
Specific Clinical Opioid Formulations:
Morphine: Prototype pure opioid agonist; available in oral, intravenous, subcutaneous, and neuraxial formulations.
Fentanyl: Highly potent, lipophilic synthetic opioid roughly more potent than intravenous morphine. Available in transdermal patches, transmucosal lozenges, buccal tablets, sublingual sprays, and intravenous forms.
Hydromorphone: Potent semi-synthetic opioid agonist roughly more potent than morphine, frequently utilized in acute post-surgical care and PCA setups.
Methadone: Unique synthetic mu-receptor agonist and N-methyl-D-aspartate (NMDA) receptor antagonist. Used to treat complex neuropathic/cancer pain and managed detoxification/maintenance for opioid use disorder. Because of its rapid absorption, complex pharmacokinetics, tissue accumulation, and prolonged elimination half-life, methadone requires cautious dose titration to prevent fatal delayed accumulation and overdose.
Adverse Effects and Management:
Common Side Effects: Nausea, vomiting, lightheadedness, pruritus, sedation, and constipation.
Management of Constipation: Unlike respiratory depression or sedation, patients do not develop pharmacological tolerance to opioid-induced constipation. Proactive bowel regimens—including daily fluid intake, dietary fiber, stimulant laxatives, and stool softeners—must be initiated alongside chronic opioid therapy.
Sedation and Respiratory Depression: Sedation reliably precedes opioid-induced respiratory depression. Clinicians monitor sedation levels using validated tools such as the Pasero Opioid-Induced Sedation Scale (POSS):
S: Sleep, easy to arouse; acceptable, no clinical intervention required.
1: Awake and alert; acceptable, no clinical intervention required.
2: Occasionally drowsy, but easy to arouse; acceptable, no clinical intervention required.
3: Frequently drowsy, drifts off to sleep during conversation; unacceptable, requires lowering the opioid dose by , maintaining close observation, and stimulating the patient to deep breathe.
4: Somnolent with minimal or absent response to physical or verbal stimuli; dangerous emergency requiring immediate cessation of the opioid, emergency administration of naloxone, and activation of emergency response protocols.
The PRODIGY Trial and Respiratory Risk Prediction: The multi-site PRODIGY trial identified five independent clinical risk factors predictive of opioid-induced respiratory depression: age (with risk increasing substantially at age ), male sex, opioid naivety, underlying sleep-disordered breathing (such as obstructive sleep apnea), and chronic heart failure (Khanna et al., 2020).
Emergency Overdose Reversal with Naloxone:
Hospital Administration: If a patient is severely somnolent, exhibits a respiratory rate below , or exhibits acute cyanosis, systemic opioids must be held and intravenous naloxone administered. Standard initial intravenous doses (typically diluted and titrated) restore respirations and wakefulness within .
Short Half-Life Warning: The systemic half-life of naloxone () is significantly shorter than the elimination half-life of most clinical opioids. As naloxone metabolizes, re-sedation and recurrent respiratory depression can emerge, requiring repeated naloxone doses every or a continuous intravenous infusion.
Community Access: The FDA has authorized naloxone formulations for community and layperson use via auto-injectors and intranasal sprays, supported by state-level standing orders and extended product shelf lives of .
Clinical Distinctions: Dependence, Tolerance, and Addiction:
Physical Dependence: A physiological state of neuroadaptation resulting from chronic drug exposure. Abrupt cessation or rapid dose reduction precipitates a predictable physical withdrawal syndrome (rhinorrhea, lacrimation, diaphoresis, severe abdominal cramping, diarrhea, piloerection, tachycardia).
Tolerance: A physiological state of adaptation where prolonged exposure to an opioid results in diminished analgesic efficacy over time, requiring progressively larger doses (sometimes up to the initial baseline dose) to achieve the original level of pain relief. Managed by dose titration or multimodal opioid-sparing strategies.
Addiction (Opioid Use Disorder - OUD): A chronic, relapsing neurobiological brain disease characterized by impaired control over drug use, compulsive craving, continued use despite documented physical, psychological, or social harm, and drug diversion (National Institute on Drug Abuse, 2020). Addiction is not an expected outcome of medically managed, short-term acute pain therapy.
Pharmacotherapy for Opioid Use Disorder (OUD): Maintenance therapies include methadone (pure mu agonist), buprenorphine (partial mu agonist), naltrexone (pure opioid antagonist), and Suboxone (a sublingual combination of buprenorphine and naloxone designed to prevent intravenous diversion).
Adjuvant Analgesics:
Medications originally developed for non-pain indications that provide direct analgesia for specific neuropathic, nociplastic, and visceral pain conditions, or that minimize opioid-induced adverse effects.
Anticonvulsants / Gabapentinoids: Gabapentin and pregabalin block voltage-gated alpha-2-delta calcium channels within the central nervous system, reducing excitatory neurotransmitter release. Highly effective for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia.
Antidepressants: Serotonin-norepinephrine reuptake inhibitors (SNRIs, such as duloxetine and venlafaxine) and tricyclic antidepressants (TCAs, such as amitriptyline and nortriptyline) enhance descending inhibitory pain pathways by blocking the reuptake of norepinephrine and serotonin. Indicated for neuropathic pain syndromes and chronic low back pain.
Alpha-2 Adrenergic Agonists: Clonidine and dexmedetomidine stimulate central alpha-2 receptors, reducing sympathetic outflow and augmenting neuraxial analgesia.
Topical Anesthetics: Transdermal lidocaine patches () provide localized sodium-channel blockade for postherpetic neuralgia without systemic toxicity.
Corticosteroids: Dexamethasone, prednisone, and methylprednisolone reduce peritumoral edema, reduce acute inflammatory compression of nerves, and alleviate metastatic bone pain.
Bisphosphonates: Inhibit osteoclast-mediated bone resorption, reducing pain from metastatic skeletal lesions and multiple myeloma.
NMDA Receptor Antagonists: Ketamine and magnesium sulfate block central NMDA receptors, reversing central sensitization, blunting hyperalgesia, and mitigating rapid opioid tolerance.
Multimodal Analgesia Principles:
Combines two or more distinct pharmacologic drug classes and nonpharmacologic therapies acting at divergent anatomical and receptor sites across the peripheral and central nervous systems (e.g., combining acetaminophen, an NSAID, a regional peripheral block, and PRN opioids).
Multimodal therapy produces additive or synergistic analgesia, lowers required individual opioid dosages, and significantly reduces the incidence of dose-dependent adverse events (such as respiratory depression, excessive sedation, and paralytic ileus; Polomano et al., 2017).
Advanced Analgesic Delivery Modalities and Routes
Patient-Controlled Analgesia (PCA):
System Mechanics: Computerized infusion pump containing a prefilled cartridge or syringe of an opioid analgesic (typically morphine, hydromorphone, or fentanyl). Connected directly to an intravenous, subcutaneous, or epidural line.
Dosing Parameters:
Loading Dose: Administered by the clinician to establish initial therapeutic blood levels.
Demand Bolus Dose: Small preset quantity of analgesic delivered when the patient presses a hand-held button.
Lockout Interval: Safety time delay programmed into the pump (typically ) during which the machine will not administer medication, even if the patient presses the button, allowing the previous dose to reach peak effect.
Basal Rate: A continuous low-dose background infusion delivered independently of patient demands. Recommended primarily for opioid-tolerant individuals and managed cautiously in opioid-naive patients due to risks of nocturnal oversedation.
Safety Safeguards and Double-Checking: The Joint Commission and the Institute for Safe Medication Practices (ISMP) require an independent double-check by two registered nurses prior to initiating or modifying PCA infusions. Nurses must verify patient identity, drug concentration, pump programming parameters, tubing integrity, and line patency.
Patient Selection Criteria: PCA requires an alert, cognitively intact patient capable of understanding the relationship between pressing the delivery button and receiving pain relief. Contraindicated in infants, confused older adults, patients with advanced dementia, individuals with severe unmonitored obstructive sleep apnea, and patients with severe motor or cognitive limitations.
The Hazard of PCA by Proxy: The practice of unauthorized family members, caregivers, or unauthorized staff pressing the PCA delivery button while the patient is asleep or sedated. This practice circumvents the primary safety mechanism of PCA (which relies on the patient falling asleep and stopping button activation before severe oversedation occurs), resulting in severe respiratory depression and fatal overdoses. Warning labels stating "WARNING: BUTTON TO BE PRESSED ONLY BY THE PATIENT" must be displayed on pump housings.
Physiologic Monitoring: Patients receiving PCA must be continuously monitored with continuous pulse oximetry and capnography (end-tidal monitoring), as capnography provides early warning of hypoventilation before hypoxia manifests on pulse oximeters.
Oral PCA Systems: Advanced wireless bedside dispensing systems allow alert hospitalized patients to self-administer scheduled and PRN oral opioid analgesics at locked, preprogrammed time intervals, reducing nursing response delays and lowering pain scores.
Continuous Subcutaneous Infusion (CSCI): Safe, effective alternative route for administering continuous opioid infusions when peripheral intravenous access is exhausted and oral intake is impossible, frequently utilized in palliative, oncologic, and hospice settings. Delivered via a small-gauge subcutaneous butterfly needle or catheter inserted into the abdomen, upper arm, or anterior chest wall at slow infusion rates (typically ).
Epidural Analgesia and Continuous Infusions:
Anatomical Catheter Placement: An anesthesiologist or certified registered nurse anesthetist inserts a specialized catheter into the mid-lumbar or thoracic interspinous space, advancing it into the epidural space between the bony ligamentum flavum and the dura mater. For temporary acute post-surgical therapy, the catheter exits over the spine and is taped over the shoulder; for permanent or long-term therapy, the line is tunneled subcutaneously around the lateral chest or abdominal wall.
Pharmacologic Combinations: Combines a lipophilic or hydrophilic opioid (fentanyl, hydromorphone, or preservative-free morphine) with a dilute local anesthetic (bupivacaine, levobupivacaine, or ropivacaine) to block sensory spinal nerve conduction.
Pharmacokinetic Onset and Duration:
Fentanyl: Highly lipophilic; rapidly penetrates spinal tissue with a clinical onset of and short duration of approximately .
Hydromorphone: Intermediate lipophilicity; onset within and duration extending up to .
Morphine: Hydrophilic; penetrates slowly with an onset of , but remains dissolved within cerebrospinal fluid (CSF) for prolonged periods, exerting analgesic effects up to , though carrying risks for delayed supraspinal rostral migration and late-onset respiratory depression.
Absolute and Relative Contraindications:
Absolute: Patient refusal, systemic sepsis, localized cutaneous infection at the lumbar insertion puncture site, severe allergy to ordered agents, and uncorrected coagulopathies or therapeutic systemic anticoagulation.
Relative: Increased intracranial pressure, severe spinal skeletal deformities, and unstable cardiovascular shock.
Evidence-Based Nursing Protocols (Guidelines for Nursing Care 36-1):
Verify the clinical prescription, drug concentration, and pump programming independently with a second registered nurse.
Keep an emergency ampule of naloxone () immediately accessible at the patient's bedside.
Use dedicated, non-intravenous epidural administration tubing without injection ports; clearly label lines, solution reservoirs, and pump housings as "For Epidural Infusion Only."
Maintain the head of the bed elevated to at least at all times (unless medically contraindicated) to prevent upward rostral migration of the opioid toward respiratory centers in the brainstem.
Monitor and document sedation scores and respiratory rates continually for the first , at least every hour () for the initial , every () up to , and at least every () thereafter until discontinuation.
Immediately notify the provider for a sedation score of or a decline in respiratory rate below .
Continuously monitor urinary output and palpate for suprapubic distension, as epidural opioids impair detrusor reflexes, requiring bladder catheterization.
Assess sensory dermatome levels and evaluate lower-extremity motor strength and bilateral leg movement every (); rapid motor paralysis indicates intrathecal catheter migration or development of an expanding spinal epidural hematoma.
Assess the catheter insertion dressing for cerebrospinal fluid leakage (clear "halo" fluid), localized erythema, purulent drainage, and bleeding.
Never administer supplementary systemic central nervous system depressants, sedatives, or concurrent opioids without formal approval from the primary anesthesiologist managing the epidural line.
Peripheral Nerve Blocks and Topical Anesthesia:
Peripheral Nerve Blocks: Infiltration or continuous catheter infusion of local anesthetics adjacent to specific somatic neural plexuses (e.g., femoral nerve block, interscalene brachial plexus block) producing temporary motor, autonomic, and sensory blockade in an operative extremity. Reduces systemic opioid requirements.
Topical Local Anesthetics:
EMLA (Eutectic Mixture of Local Anesthetics): Contains lidocaine and prilocaine cream. Applied topically under an occlusive dressing for a minimum contact dwell time of prior to venipuncture, lumbar puncture, or bone marrow biopsy in pediatric patients.
LMX-4 (Formerly ELA-Max): Over-the-counter liposomal lidocaine formulation that achieves deep cutaneous analgesia in or less without requiring strict occlusive wrap.
Continuous Wound Infiltration Systems (ON-Q Pain Relief System): An elastomeric balloon reservoir that automatically delivers continuous, controlled infusions of local anesthetic directly into the surgical wound bed through a fenestrated intraoperative catheter over several days, improving early mobility and lowering systemic opioid consumption.
Special Clinical Populations and Pain Treatment Regimens
Acute Postoperative Pain Management:
Preventing acute pain is clinically superior to treating severe established pain. Providers must avoid PRN schedules in early postoperative periods, utilizing around-the-clock (ATC) regimens, continuous infusions, or patient-controlled modalities.
Analgesic dosing should be coordinated with nursing activities (e.g., offering oral analgesics prior to physical therapy or ambulation) to ensure peak plasma levels occur during maximal functional exertion.
Cancer Pain and Chronic Pain Management:
Foundational Principles: Provide medications via the oral route whenever clinically possible; administer long-acting analgesics around-the-clock (ATC) to maintain steady therapeutic plasma levels; proactively titrate doses to balance comfort against side effects; and maximize patient autonomy.
World Health Organization (WHO) Three-Step Analgesic Ladder:
Step 1 (Mild Pain, ): Nonopioid analgesics (acetaminophen, NSAIDs) adjuvant analgesics.
Step 2 (Moderate Pain, ): Mild-to-moderate potency opioid formulations (codeine, tramadol, low-dose oxycodone) nonopioid analgesics adjuvant agents.
Step 3 (Severe / Excruciating Pain, ): High-potency opioid agonists (morphine, hydromorphone, fentanyl, methadone) titrated aggressively to comfort nonopioid analgesics adjuvants.
Clinical Efficacy: The WHO ladder provides relief for to of patients experiencing cancer pain. Patients with refractory pain require Step 4 interventions, including epidural/intrathecal pumps, neurolytic blocks, or surgical neuromodulation.
Application to Acute Pain: Management of acute post-surgical or severe traumatic pain superimposes an inverted progression onto the ladder: therapy begins aggressively at Step 3 with strong systemic opioids and regional techniques, stepping down to Step 2 and Step 1 agents as tissue healing progresses (Gai et al., 2020).
Management of Breakthrough Pain (BTP / BTcP):
Definition: A sudden, transitory flare-up of moderate-to-severe pain that erupts over baseline chronic pain otherwise well-controlled by around-the-clock (ATC) background analgesia. Affects up to of patients with advanced cancer.
Subtypes: Classified as incident pain (provoked predictably or unpredictably by voluntary actions such as walking, or involuntary movements such as coughing) or idiopathic pain (spontaneous, unexpected eruption without an identifiable trigger).
BTP vs. End-of-Dose Failure: End-of-dose pain occurs predictably immediately prior to the scheduled administration of the next regular ATC dose, signaling that the baseline long-acting opioid dose must be increased or the dosing interval shortened. True breakthrough pain is managed with supplementary, short-acting, rapid-onset transmucosal, sublingual, or intranasal fentanyl formulations on an as-needed basis.
Pediatric Pain Management:
Postoperative analgesia must be administered around-the-clock (ATC) or via continuous infusions, rather than PRN. Pain associated with minor clinical procedures (phlebotomy, wound care) must be treated preemptively using multimodal combinations of topical local anesthetics and nonpharmacologic distraction.
Opioid therapy is safe and effective in pediatric cancer and postoperative settings; withholding opioids from pediatric patients due to unfounded fears of clinical addiction is clinically unacceptable.
Geriatric Pain Management:
The Clinical Rule: "Start low and go slow." Initial doses for older adults should be initiated at to of standard young-adult starting doses, with cautious upward titration.
Pharmacologic Selection:
Acetaminophen: First-line agent for mild-to-moderate musculoskeletal pain.
NSAIDs: Use with extreme caution. Limit to the lowest effective dose for the absolute shortest duration possible, pairing with proton pump inhibitors when necessary, due to elevated risks of renal toxicity, gastrointestinal hemorrhage, and cardiovascular events.
Opioids: Indicated for moderate-to-severe chronic pain that impairs functional status and quality of life when alternatives fail. Regular monitoring for oversedation, cognitive delirium, fall risk, and constipation is required.
Adjuvants: Low-dose gabapentinoids and SNRIs for neuropathic pain syndromes. Tricyclic antidepressants should generally be avoided due to severe anticholinergic properties (urinary retention, cardiac arrhythmias, confusion).
Ethical, Legal, and Health Policy Dimensions of Pain Management
The Fundamental Right to Pain Management:
Patients possess a legal and ethical right to have their pain validated, thoroughly assessed, and treated with dignified, evidence-based multimodal strategies. Clinicians have an ethical obligation to believe patient self-reports and act as clinical advocates.
The Role of the Pain Resource Nurse (PRN):
Established in institutional healthcare systems since the 1990s, the PRN is a clinical staff nurse who receives specialized training in pain management and interprofessional collaboration. The PRN acts as a peer mentor, implements hospital pain protocols, leads quality improvement initiatives, and ensures evidence-based standards are translated into direct patient care (Allen et al., 2018; Crawford et al., 2016).
National Institutes of Health (NIH) HEAL Initiative:
The NIH Helping to End Addiction Long-term (HEAL) Initiative represents an aggressive federal transagency initiative funding clinical, translational, and basic science research to improve non-addictive pain therapies, optimize treatments for opioid use disorder (OUD), and mitigate the national opioid overdose epidemic.
The Ethics of Placebo Administration:
Placebo Definition: Any active-appearing sham medication, intervention, or procedure knowingly devoid of specific clinical therapeutic value (derived from the Latin meaning "I shall please").
Placebo vs. Nocebo Effects: The placebo effect represents an actual psychophysiological therapeutic response (such as endogenous endorphin release) triggered by the patient's expectation of relief and therapeutic trust in the clinician. Conversely, the nocebo effect is an adverse, undesirable outcome (nausea, severe anxiety, worsening pain) provoked by negative anticipatory expectations.
Professional and Ethical Prohibitions: Utilizing a deceptive placebo outside of an Institutional Review Board (IRB)-approved, double-blind clinical trial violates fundamental ethical principles of autonomy, informed consent, and veracity. Administering a placebo breaks clinical trust, damages therapeutic alliances, and constitutes deceptive practice. Professional bodies—including the American Nurses Association (ANA), the American Society of Pain Management Nurses (ASPMN), the Oncology Nursing Society (ONS), and the American Pain Society (APS)—explicitly condemn the deceptive administration of placebos in clinical nursing practice. Nurses have clear ethical and legal obligations to refuse to administer unauthorized placebos (Arnstein et al., 2011).
Societal, Racial, and Legal Dimensions of Drug Policy:
The modern "war on drugs" and historical criminalization paradigms have disproportionately targeted low-income populations and communities of color, creating disparities in healthcare access, untreated pain, and mass incarceration.
Multidisciplinary bioethicists, psychologists, and clinicians advocate shifting substance use management from criminal justice systems toward restorative public health models and social support structures (Earp et al., 2021; Hart, 2021).
Clinical investigations explore regulated novel therapies—such as phase 3 trials of MDMA-assisted psychotherapy for severe posttraumatic stress disorder (PTSD)—to expand neuropsychiatric and pain management care (Mitchell et al., 2021).
Systematic Evaluation of Pain Interventions
Ongoing Evaluative Cycle:
Evaluation is a continuous clinical responsibility that assesses the changing nature of the patient's pain experience, the effectiveness of pharmacologic and nonpharmacologic interventions, and the patient's progress toward functional comfort goals.
Evaluating Dynamic Pain Trajectories:
Decreasing Pain Intensity: May reflect healing of underlying pathology or indicate that the current analgesic regimen is effective and should be maintained.
Increasing Pain Intensity: Does not merely indicate the need for higher medication doses; it serves as a critical warning that underlying disease pathology has changed, deteriorated, or that a new surgical complication has emerged (e.g., compartment syndrome, expanding visceral perforation, localized abscess).
Evaluating Multi-modal Regimens:
Clinicians must critically re-evaluate whether every prescribed medication, route, and dosing interval remains therapeutic, monitoring for subtle adverse effects (such as progressive cognitive dulling, urinary hesitancy, or mild motor ataxia).
If a nonpharmacologic intervention (e.g., guided imagery or biofeedback) produces agitation, restlessness, or frustration, the nurse terminates the modality and substitutes an alternative technique matched to patient preferences.
Patient and Family Goals and Satisfaction:
Complete elimination of pain () is rarely a realistic or safe goal in major surgical trauma or chronic disease. Successful pain management is achieved when the patient meets their mutually established functional comfort goals, carries out necessary rehabilitative activities without distress, and expresses satisfaction with the dignity and responsiveness of their care.